tcsc2323 Nedocromil

Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C₄ (LTC₄), and prostaglandin D₂ (PGD₂).

IC50 & Target: Histamine, LTC₄, PGD₂^[1]

In Vitro: Nedocromil inhibits the release of histamine, LTC₄, and PGD₂ from mast cells challenged with antigen (with IC₃₀ values of 2.1 μM, 2.3 μM, and 1.9 μM, respectively) and with anti-human IgE (IC₃₀ values of 4.7 μM, 1.3 μM, and 1.3 μM, respectively)^[1].

In Vivo: Nedocromil-treated diabetic mice show significantly improved heart function compared with controls. The contractility and relaxation forces show similar improvements. However, the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice. Nedocromil can significantly improve cardiac function in mice with diabetic cardiomyopathy, but the treatment cannot restore normal function^[2].